Summarizing the FIELD study: lessons from a 'negative' trial.

Abstract:

INTRODUCTION:Disturbances in lipid metabolism represent an integral component of dysglycemic states and may increase the risk of diabetic complications. Although from a pathophysiological viewpoint fibrates could represent the ideal drug for patients with diabetic dyslipidemia the evidence that support their use in these patients remains elusive. The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study was a double-blind, placebo-controlled trial that randomized 9795 diabetic subjects to fenofibrate or matching placebo for an average of 5 years. AREAS COVERED:In this review, all the findings of the FIELD trial are summarized. EXPERT OPINION:Chronic kidney disease (reduced GFR, albuminuria or both) and the presence of metabolic syndrome significantly increase the cardiovascular risk in patients with diabetes. Fenofibrate may represent a useful therapeutic option for the treatment of atherogenic dyslipidemia in diabetic subjects. Further attention should be paid on the unique microvascular-protecting properties of the drug.

authors

Tsimihodimos V,Mikhailidis DP,Elisaf M

doi

10.1517/14656566.2013.850075

subject

Has Abstract

pub_date

2013-12-01 00:00:00

pages

2601-10

issue

18

eissn

1465-6566

issn

1744-7666

journal_volume

14

pub_type

杂志文章,评审
  • The value of irbesartan in the management of hypertension.

    abstract::Elevated blood pressure levels are highly prevalent and are a major reason for cardiovascular events and thus place a significant financial burden on healthcare systems worldwide. Guidelines recommend five first-line anti-hypertensive drug classes, but compelling indications may indicate favoring one drug class over a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903103820

    authors: Bramlage P,Durand-Zaleski I,Desai N,Pirk O,Hacker C

    更新日期:2009-08-01 00:00:00

  • Treatment of adult short bowel syndrome patients with teduglutide.

    abstract:INTRODUCTION:Parenteral support is lifesaving in short bowel syndrome patients with intestinal failure (SBS-IF), who are unable to compensate for their malabsorption by metabolic or pharmacologic adaptation. Mutually, the symptoms of SBS-IF and the inconveniences and complications in relation to parenteral support may ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.644787

    authors: Nørholk LM,Holst JJ,Jeppesen PB

    更新日期:2012-02-01 00:00:00

  • Review of vorapaxar for the prevention of atherothrombotic events.

    abstract:INTRODUCTION:Atherosclerosis is frequently caused by clot blockage of the coronary or peripheral arteries, and may lead to myocardial infarction (MI) or peripheral arterial disease (PAD). Despite advancements in management of atherosclerosis, mortality and ischemic rates remain high. Vorapaxar is a protease activated r...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1099629

    authors: Wang A

    更新日期:2015-01-01 00:00:00

  • A pharmacoeconomic appraisal of therapies for hepatitis B and C.

    abstract::In the recent years, advances in the treatment of chronic hepatitis B and C have shown that newer, more expensive therapy may result in higher sustained viral response rates. In light of this, the pertinent question for healthcare decision-makers centres around whether this increase in efficacy 'justifies' the additio...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.2.205

    authors: Younossi ZM,Temple ME,Shermock KM

    更新日期:2001-02-01 00:00:00

  • A pharmacogeneticist's look at drug effects and the drug development process: an overview.

    abstract::This paper describes the functional roles of the closely related pharmacogenetic and pharmacogenomic sciences in medicine. Firstly, they provide means for a better understanding of the function of drugs, and particularly of the differences of drug action between individuals and also between racially categorised popula...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.8.1299

    authors: Kalow W

    更新日期:2005-07-01 00:00:00

  • Current and future therapies for the treatment of histamine-induced angioedema.

    abstract:INTRODUCTION:Angioedema, a sudden, self-limited swelling of localized areas of any part of the body that may or may not be associated with urticaria, is thought to be the result of a mast-cell mediated process versus a bradykinin etiology. Understanding the mechanism is key in determining the proper treatment. Areas Co...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1282461

    authors: James C,Bernstein JA

    更新日期:2017-02-01 00:00:00

  • Anorexia in end-stage renal disease: pathophysiology and treatment.

    abstract::Anorexia is a frequent complication of uraemic syndrome, which contributes to malnutrition in dialysis patients. Uraemic anorexia has been associated with many factors. This paper reviews the current knowledge about mechanisms responsible for uraemic anorexia, the treatments and new drugs used to control the loss of a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.11.1825

    authors: Aguilera A,Selgas R,Diéz JJ,Bajo MA,Codoceo R,Alvarez V

    更新日期:2001-11-01 00:00:00

  • New treatment options for panic disorder: clinical trials from 2000 to 2010.

    abstract:INTRODUCTION:Panic disorder (PD) is a prevalent psychiatric disorder characterized by unexpected and recurrent panic attacks. PD patients present significant psychosocial impairment and a high risk of psychiatric comorbidities and suicide. PD should be treated effectively as soon as the symptoms emerge because the long...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.562200

    authors: Freire RC,Hallak JE,Crippa JA,Nardi AE

    更新日期:2011-06-01 00:00:00

  • An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis.

    abstract:INTRODUCTION:Moderate-to-severe AD burdens a large proportion of AD patients and may represent an inadequacy of treatment options available for resistant disease. AREAS COVERED:This review provides an overview of the therapies for moderate-to-severe AD in late-stage development and in the clinic, and focuses on barici...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,评审

    doi:10.1080/14656566.2020.1739268

    authors: Mendes JT,Balogh EA,Strowd LC,Feldman SR

    更新日期:2020-06-01 00:00:00

  • Glatiramer acetate for the treatment of multiple sclerosis.

    abstract::Glatiramer acetate (Copaxone, Teva Pharmaceuticals Ltd) is a collection of immunomodulatory, synthetic polypeptides indicated for the treatment of relapsing-remitting multiple sclerosis (RR MS). Preclinical and clinical studies provide an evolving understanding of the mechanisms by which glatiramer acetate exerts both...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.4.875

    authors: Wolinsky JS

    更新日期:2004-04-01 00:00:00

  • Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression.

    abstract:BACKGROUND:This study aimed to analyze the characteristics and outcomes of patients suffering from non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor mutations (EGFRm+) receiving gefitinib who remained clinically stable following confirmation of progressive disease (PD) using Response Evaluation C...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2018.1484903

    authors: Hosomi Y,Tanai C,Yoh K,Goto Y,Sakai H,Kato T,Kaburagi T,Nishio M,Kim YH,Inoue A,Hasegawa Y,Isobe H,Tomizawa Y,Mori Y,Minato K,Yamada K,Ohashi Y,Kunitoh H

    更新日期:2018-07-01 00:00:00

  • Recent advances in the medical therapy of Crohn's disease in childhood.

    abstract::Crohn's disease (CrD) is characterised by an ongoing inflammatory response in the gut, in the absence of an obvious trigger. The treatment of CrD in children, during relapse and remission, requires special consideration of growth and development. This review addresses the use of present medical management strategies, ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.15.2553

    authors: Bremner AR,Beattie RM

    更新日期:2007-10-01 00:00:00

  • Therapeutic options for Acinetobacter baumannii infections.

    abstract::Acinetobacter baumannii is an important cause of nosocomial infections, mainly in patients in intensive care units. This microorganism, although with slight differences depending on the country, presents resistance to multiple antimicrobial agents, occasionally including resistance to colistin: hence, it can be consid...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.4.587

    authors: Vila J,Pachón J

    更新日期:2008-03-01 00:00:00

  • Acute promyelocytic leukemia: what are the treatment options?

    abstract:IMPORTANCE OF THE FIELD:Acute promyelocytic leukemia (APL) represents a paradigm of therapeutic success in clinical hematology. Since the introduction of all-trans-retinoic-acid in the early 1980s, complete remission rates exceed 90% and the cure rate is > 70%. Notwithstanding, various questions concerning the manageme...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903505115

    authors: Ferrara F

    更新日期:2010-03-01 00:00:00

  • Pediatric status epilepticus: improved management with new drug therapies?

    abstract:INTRODUCTION:Status Epilepticus (SE) is the most common neurological emergency of childhood. It requires prompt administration of appropriately selected anti-seizure medications. Areas covered: Following a distinction between estabilished and emergent drugs, we present pharmacological treatment options and their clinic...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1323873

    authors: Verrotti A,Ambrosi M,Pavone P,Striano P

    更新日期:2017-06-01 00:00:00

  • Review of the use of topotecan in ovarian carcinoma.

    abstract::Ovarian cancer is the fifth leading cause of cancer deaths in women. The majority of patients present with advanced disease and relapse after first-line platinum-based chemotherapy; therefore, many proceed to treatment with salvage chemotherapy. Currently available treatment options are generally no longer curative in...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.11.2333

    authors: Ahmad T,Gore M

    更新日期:2004-11-01 00:00:00

  • Miconazole, a pharmacological barrier to skin fungal infections.

    abstract:INTRODUCTION:Miconazole (MCZ) is a time-honored antifungal of the imidazole class. MCZ exerts a multipronged effect on fungi. It inhibits the cytochrome P450 complex, including the 14α-demethylase enzyme required for ergosterol biosynthesis, in fungal cell membranes. In addition, intracellular accumulation of toxic met...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.687047

    authors: Piérard GE,Hermanns-Lê T,Delvenne P,Piérard-Franchimont C

    更新日期:2012-06-01 00:00:00

  • A new ketoconazole topical gel formulation in seborrhoeic dermatitis: an updated review of the mechanism.

    abstract::Seborrhoeic dermatitis (SD) is a chronic, inflammatory skin disorder, affecting areas of the head and body where sebaceous glands are most prominent and active. The disorder commonly affects hair-bearing areas of the head, including the scalp. Involvement on the face is usually limited to the hairline, eyebrows, nasol...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.9.1365

    authors: Faergemann J,Borgers M,Degreef H

    更新日期:2007-06-01 00:00:00

  • Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension.

    abstract::Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition. Sitaxsentan, a selective endothelin-A receptor antagonist, is an effective, safe and well-tolerated endothelin receptor antagonist for the treatment of PAH in adult patients. Multi-center, randomized, placebo-controlled clinical trials...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.1.95

    authors: Barst RJ

    更新日期:2007-01-01 00:00:00

  • Several options for antiviral treatment trials in multiple sclerosis--but which targets should be selected?

    abstract::Involvement of viruses in the pathogenesis of multiple sclerosis (MS) is a long-lived hypothesis, which is has not yet been proven nor refuted. This is partly due to difficulties in the evaluation of diagnostic findings on persistent infections by common viruses such as herpesviruses and endogenous retroviruses. Progr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.6.1087

    authors: Bergström T

    更新日期:2000-09-01 00:00:00

  • Opioids in the treatment of postoperative pain: old drugs with new options?

    abstract::New approved options with opioids in the postoperative setting may include new ways of administration, new combinations with other drugs and new opioid drugs. Newly approved devices for administration include sublingual sufentanil dispenser and transdermal iontophoretic fentanyl, with the purpose of almost mimicking t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.2014.879292

    authors: Raeder J

    更新日期:2014-03-01 00:00:00

  • Ribavirin--current status of a broad spectrum antiviral agent.

    abstract::Ribavirin is a very broad-spectrum virustatic antiviral agent, first synthesised in 1972. It is characterised by low toxicity apart from reversible anaemia, usually mild. Its multiple mechanisms of action mean that viral resistance rarely develops. It can be administered orally, intravenously, or via a nebuliser. It h...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.8.1317

    authors: Snell NJ

    更新日期:2001-08-01 00:00:00

  • Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.

    abstract:INTRODUCTION:A residual risk of morbidity and mortality from cardiovascular (CV) disease remains despite statin therapy. This situation has generated an interest in finding novel approaches of combining statins with other lipid-lowering agents, or finding new lipid and non-lipid targets, such as triglycerides, high-den...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1118055

    authors: Serban MC,Banach M,Mikhailidis DP

    更新日期:2016-01-01 00:00:00

  • Anti-thrombotic therapy in cancer patients.

    abstract::Primary and secondary prevention of venous thromboembolism (VTE) are the major roles of anti-thrombotic therapy in patients with cancer. Although the choices of pharmacological agents remain limited, low molecular weight heparins (LMWHs) offer important advantages over traditional anticoagulants. For prophylaxis in th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.12.2213

    authors: Lee AY

    更新日期:2003-12-01 00:00:00

  • Latest treatment strategies for membranous nephropathy.

    abstract::Thirty to forty percent of patients with idiopathic membranous nephropathy have persistent heavy proteinuria and may progress to end-stage kidney disease in 5 - 15 years. The ideal treatment for these patients is a matter of debate. Several nonspecific immunosuppressive regimens have been suggested with the aim of red...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.18.3159

    authors: Ruggenenti P,Cravedi P,Remuzzi G

    更新日期:2007-12-01 00:00:00

  • The treatment of Tourette's syndrome: current opinions.

    abstract::Correct education of the patient is one of the most important aspects in the treatment of Tourette's syndrome. Pharmacotherapy is often unsatisfactory and therefore should be limited to those patients who are significantly impaired. Therapy must be individualised and the most troublesome symptom should be targeted fir...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.7.899

    authors: Müller-Vahl KR

    更新日期:2002-07-01 00:00:00

  • Langerhans cell histiocytosis: pragmatic empirism on the road to rational cure.

    abstract::Langerhans cell histiocytosis (LCH) is a rare disease characterized by the accumulation of clonal dendritic cells in different organs. Most recent findings (e.g., activating BRAF mutations) favor the hypothesis that LCH may represent a neoplasm with varying behavior, but the ultimate pathogenesis remains to be uncover...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 评论,社论

    doi:10.1517/14656566.2012.698612

    authors: Minkov M

    更新日期:2012-08-01 00:00:00

  • Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary.

    abstract::Peglyated liposomal doxorubicin was developed to maintain or enhance the demonstrated antineoplastic effects of doxorubicin, while improving the toxicity profile associated with this important cytotoxic agent. Accumulating clinical data have confirmed the activity of pegylated liposomal doxorubicin in cancers of the b...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.7.11.1469

    authors: Markman M

    更新日期:2006-08-01 00:00:00

  • Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?

    abstract::Introduction: Multiple sclerosis (MS) is a demyelinating disease, causing axonal damage and disability. Dalfampridine (DAL) is an extended-release formulation of 4-aminopyridine (4AP) and broad-spectrum voltage-dependent potassium channel blocker that is reported to improve motor, visual and cognitive functions. Furth...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2019.1623879

    authors: Foschi M,Lugaresi A

    更新日期:2019-08-01 00:00:00

  • Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.

    abstract:INTRODUCTION:Increasing population age, obesity and physical inactivity mean that type 2 diabetes mellitus (T2DM) is increasingly common. Current treatments may be limited by adverse events, drug-drug interactions or contraindication/need for dose adjustment in patients with renal impairment. AREAS COVERED:This paper ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.642863

    authors: Forst T,Pfützner A

    更新日期:2012-01-01 00:00:00